Glycerol monolaureate (GML), also known as monolaurin, is a monoglyceride commonly studied for its antimicrobial properties, including activity against fungi. The scientific evidence supporting its use for fungal infections comes primarily from in vitro (laboratory) studies. These studies have demonstrated that GML can disrupt the cell membranes of various pathogenic fungi, including Candida albicans, leading to inhibited growth or cell death. The proposed mechanism involves GML's ability to solubilize lipid bilayers, which compromises the integrity of fungal cell membranes.

However, evidence in humans is limited. There are no large-scale clinical trials or robust human studies evaluating the efficacy of GML as a treatment for fungal infections. Most available research is preclinical and does not directly translate to proven clinical benefits. GML is not a standard therapy for fungal infections, and its use is not widely endorsed in clinical guidelines. Nonetheless, some dietary supplements and topical preparations include GML for purported antifungal benefits, likely based on these preliminary laboratory findings.

In summary, while scientific studies provide a rationale for antifungal effects of GML in controlled laboratory settings, clinical evidence in humans is lacking. Until more high-quality clinical research is available, GML should not be considered a primary or sole treatment for fungal infections.